Nominations for the 2014 award are now closed.
View the list of all prior recipients.
The American Association for Cancer Research established this award in 2007 in honor of Margaret Foti, Ph.D., M.D. (h.c.), for her exemplary leadership of the AACR as its chief executive officer; for her sustained, outstanding work in fostering research, scholarly communications, education and training, science policy and public education; and for her extraordinary dedication and contributions to the conquest of cancer.
This award recognizes a true champion of cancer research, an individual who embodies the sustained commitment of Margaret Foti to the prevention and cure of cancer. The award is given to an individual whose leadership and extraordinary achievements in cancer research or in support of cancer research have made a major impact on the field. Such achievements include contributions to the acceleration of progress in cancer research, raising national or international awareness of cancer research, or other demonstrations of a sustained commitment to the conquest of cancer.
The Eighth Annual Award will be presented at the AACR Annual Meeting 2014, in San Diego, CA, USA (April 5-9, 2014). The recipient must be present to receive the award unless otherwise unable to do so because of health restrictions or other serious conflicts.
The recipient will receive an honorarium of $10,000, a commemorative award, and support for the winner and a guest to attend the AACR Annual Meeting.
- Candidacy is open to all individuals who are affiliated with any organization whose mission supports cancer research or any institution involved in cancer research, cancer medicine or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry or government.
- Institutions or organizations are not eligible for the award.
- Selection of the award winner will be made on the basis of the candidate's sustained commitment to accelerating progress in cancer research. No regard will be given to race, gender, nationality, geographic location or religious or political views.
Nominations are closed.
Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science. Candidates may not nominate themselves.
There is no restriction on the number of candidates that may be nominated by any individual scientist. There is no restriction on the number of nominators that may write nomination letters or that may sign a single nomination letter on behalf of a candidate.
Nomination Materials to be submitted are:
1) Nomination Letter Must:
- be addressed to the Selection Committee; be written in English; and not exceed 1,000 words;
- specify the AACR Award for which the candidate is being nominated;
- describe the candidate’s leadership and extraordinary achievements in cancer research; and
- be signed by the nominator(s).
2) Candidate's CV. The candidate's curriculum vitae in English, including a complete list of the candidate's publications.
3) Summary Statement. A statement, no more than 50 words, summarizing the candidate's research accomplishments for which he or she is being nominated.
Nominatins must be emailed to email@example.com by 4:00 p.m. United States Eastern Time on Thursday, September 26, 2013. Paper nominations will not be accepted. Full nomination instructions and program guidelines are available through the link below.
Candidates for the award will be considered by a prestigious committee of renowned international cancer leaders appointed by the president of the AACR. After careful deliberations by the committee, their recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision.
Selection of the award winner will be made on the basis of the leadership and extraordinary achievements of the candidate. No regard will be given to race, gender, nationality, geographic location, or religious or political views.
Linda Stokes, Program Associate
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
Seventh Annual Award Recipient
Robert C. Young, M.D.
Dr. Young received his award during the Opening Ceremony at the AACR Annual Meeting 2013 in Washington, D.C. The award presentation was held on Sunday, April 7, 2013. Visit the AACR Annual Meeting 2013 page for more information.
Dr. Robert C. Young is recognized for his pioneering work in the fields of lymphoma and ovarian cancer, and for his leadership roles in multiple organizations.
Dr. Young is one of the country's most respected and recognized clinical investigators and oncology leaders. His contributions to cancer research span over 4 decades in which he has made significant contributions to the treatment of Hodgkin's disease, lymphomas, and ovarian cancer. His early focus on the neglected field of ovarian cancer research has led to a robust worldwide clinical structure of national and international cooperative group trials, substantial SPORE and DOD programs in ovarian cancer, and the standardized staging and grading of the tumor.
Dr. Young's contributions began at the Medicine Branch of the National Cancer Institute where he was part of a leadership team that demonstrated the curability of advanced Hodgkin's disease and diffuse lymphoma with combination chemotherapy. Dr. Young rose to head the Medicine Branch of the NCI where he served for 14 years during which he trained many of the Medical Oncology leaders of today including three recent Presidents of ASCO.
Under Dr. Young's leadership, his group developed a strategy for progress, established the first ovarian cancer cell lines, stimulated clinical trial development on national scale, characterized and standardized staging, grading, and prognostic factors an published the first randomized clinical trial establishing combination chemotherapy as the preferred treatment for advanced disease.
After moving to Fox Chase Cancer Center to become President and CEO, Dr. Young continued his work on ovarian cancer and led national clinical trials in early stage ovarian cancer, which have established the standard of care and, with his colleagues Drs. Ozols and Bookman, established Carboplatin and Taxol as the standard of care in advanced disease. For this body of work, he and Dr. Ozols shared the Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research. Numerous patients have benefited as a result of the work of Dr. Young and his colleagues. He has served as the Chairman of the Board of Scientific Advisors of the National Cancer Institute, and President of American Society of Clinical Oncology, the American Cancer Society and the International Gynecologic Cancer Society.